Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Win Ratio Analysis of Edoxaban vs Dalteparin in Cancer-Associated VTE – JTH
Feb 24, 2026, 13:29

Win Ratio Analysis of Edoxaban vs Dalteparin in Cancer-Associated VTE – JTH

Journal of Thrombosis and Haemostasis shared a post on LinkedIn about a recent article by Nick van Es et al, adding:

”The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE Cancer trial

Novel win ratio analysis comparing edoxaban versus dalteparin in cancer-associated VTE reveals no significant difference between treatments when evaluating hierarchically prioritized outcomes including mortality, recurrent events, and bleeding complications.”

Title: The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial

Authors: Nick van Es, Luuk J.J. Scheres, Kristen M. Sanfilippo, Harry Büller, Marc Carrier, Marcello Di Nisio, Michael Grosso, Renato D. Lopes, William F. McIntyre, Bjorn Redfors, Annelise Segers, Peter Verhamme, Jeffrey I. Weitz, Patrick M. Bossuyt, Deborah M. Siega

Read the Full Article on Journal of Thrombosis and Haemostasis.

Win Ratio Analysis of Edoxaban vs Dalteparin in Cancer-Associated VTE - JTH

Stay updated with Hemostasis Today.